GLP-1 Drugs and Nutrient Deficiencies: Vitamin D, Iron & Protein
A 2026 study of 2,031 teens on GLP-1 drugs went viral for its vitamin D number. Here is what it actually measured, how it compares with adult data, and what it does not prove.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar — your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
How It Works
GLP-1 drugs work by cutting appetite. A 2026 review describes micronutrient risk as coming from several interacting drivers: reduced food intake, lower dietary diversity, GI intolerance, delayed gastric emptying, rapid weight loss and pre-existing baseline risk. It does not rank any single one of these as the main cause.
Nausea, vomiting and delayed gastric emptying can further cut intake. In the STEP TEENS trial, gastrointestinal adverse events occurred in 62% of adolescents on semaglutide vs 42% on placebo.
Delayed gastric emptying, slower small-intestine motility and lower gastric acid have been proposed as reasons iron absorption could fall on incretin drugs. These mechanisms are proposed, not yet confirmed by mechanistic studies.
Children and adolescents with obesity already have a higher risk of vitamin D deficiency than normal-weight peers (relative risk 1.41 in a 20-study meta-analysis), before any drug enters the picture.
What the Data Shows
Key Takeaways
- In a 2026 US claims study of 2,031 GLP-1 users aged 10-17 with no prior deficiency diagnosis, 16.88% were diagnosed with a nutritional deficiency or related complication within a year; vitamin D deficiency was the most common at 12.4%.
- Only 23.3% of those teens had a nutrition therapy or counseling visit within 180 days, and the average wait for a first visit was 149 days.
- Adult claims data show a similar pattern: 22.4% of 461,382 new GLP-1 users had a deficiency diagnosed within 12 months, with vitamin D deficiency at 13.6%.
- In a diet-diary study of 387 adults on GLP-1 or dual GIP/GLP-1 drugs, average intake was 753 kcal and 33.4 g protein per day, and fewer than 10% met protein recommendations.
- A 2025 joint advisory from four obesity and nutrition societies recommends baseline nutrition screening, preventing nutrient deficiencies, and preserving muscle with resistance training and appropriate diet during GLP-1 treatment.
- Whether GLP-1 drugs cause these deficiencies: the pediatric study did not compare against teens who were not taking a GLP-1, and a review of the adult evidence says causality cannot be definitively established.
- True deficiency rates: claims data count diagnosis codes, which depend on who gets tested, so they are not the same as lab-measured prevalence.
- Why teens who saw a nutrition professional had more recorded deficiencies (23.2% vs 14.8%): the study reports the difference but cannot say whether counseling visits simply led to more testing.
- How current drugs compare: 78.6% of the teens were on liraglutide (2017-2022 data), so results for semaglutide or tirzepatide in teens are not settled.
- Evidence-based monitoring schedules: reviews call for prospective studies to define incidence, clinical relevance and monitoring strategies, and no established guideline exists yet for iron deficiency on these drugs.
Frequently Asked Questions
Do GLP-1 drugs cause vitamin D deficiency in kids?
Not proven. A 2026 claims study found 12.4% of 2,031 teens starting a GLP-1 were diagnosed with vitamin D deficiency within a year, but it had no comparison group of teens not on the drugs. Children with obesity already carry a higher vitamin D deficiency risk, so part of that number may reflect baseline risk and testing.
What did the 2026 pediatric GLP-1 nutrition study find?
Kerr and colleagues (Childhood Obesity, 2026) analyzed insurance claims for 2,031 GLP-1 users aged 10-17. Within a year, 16.88% were diagnosed with a nutritional deficiency or related complication, most often vitamin D deficiency (12.4%), then nutritional anemia (1.55%) and iron-deficiency anemia (1.44%). Only 23.3% saw nutrition counseling within 180 days.
Is protein intake a problem on GLP-1 drugs?
It can be. In a 2026 diet-diary study of 387 adults on GLP-1 or dual GIP/GLP-1 drugs, average intake was 753 kcal and 33.4 g of protein a day, and fewer than 10% met protein recommendations. Higher protein intake was associated with more weight loss in that sample, which was recruited from social media support groups.
Can GLP-1 drugs cause iron deficiency?
Early observational data suggest it is possible but currently uncommon. A 2026 review proposes lower iron intake and reduced absorption from delayed gastric emptying and lower stomach acid as mechanisms, says these need confirmation, and notes no established guideline yet exists. In the pediatric cohort, iron-deficiency anemia was diagnosed in 1.44% within a year.
Which nutrients get the most attention on GLP-1 drugs?
Reviews most often flag iron, vitamin B12, vitamin D, calcium, magnesium and zinc, plus protein adequacy. Risk is higher with prior bariatric surgery, GI disorders, poor baseline diet, older age or prolonged nausea and vomiting. Monitoring should be individualized with the prescribing clinician; this is not medical advice.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
GLP-1 drugs are prescription medications. Decisions about testing, supplements or dosing, especially for children and teens, belong with the prescribing clinician or pediatrician.
Observational claims data show associations, not cause and effect.